Holen Sie sich die Stockscreener-App
140.67
0.52%
0.73
Handel nachbörslich:
141.05
0.38
+0.27%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$139.94
Offen:
$140.13
24-Stunden-Volumen:
1.56M
Relative Volume:
1.13
Marktkapitalisierung:
$20.62B
Einnahmen:
$9.61B
Nettoeinkommen (Verlust:
$1.53B
KGV:
13.45
EPS:
10.46
Netto-Cashflow:
$1.85B
1W Leistung:
+6.39%
1M Leistung:
+5.85%
6M Leistung:
-2.16%
1J Leistung:
-30.29%
1-Tages-Spanne:
$139.96
$144.20
1-Wochen-Bereich:
$133.53
$145.27
52-Wochen-Spanne:
$110.03
$204.18
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
140.67 | 20.52B | 9.61B | 1.53B | 1.85B | 10.46 |
|
LLY
Lilly Eli Co
|
727.21 | 665.99B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
178.43 | 430.51B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
212.56 | 376.28B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
129.73 | 248.60B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
84.71 | 209.94B | 63.43B | 16.42B | 14.72B | 6.49 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Cinctive Capital Management LP Buys Shares of 7,894 Biogen Inc. $BIIB - MarketBeat
Focus Partners Advisor Solutions LLC Makes New $725,000 Investment in Biogen Inc. $BIIB - MarketBeat
Amundi Grows Holdings in Biogen Inc. $BIIB - MarketBeat
Vident Advisory LLC Grows Stake in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. (NASDAQ:BIIB) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Evergreen Capital Management LLC Acquires New Position in Biogen Inc. $BIIB - MarketBeat
Landscape Capital Management L.L.C. Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Priya Singhal Sells 517 Shares of Biogen (NASDAQ:BIIB) Stock - MarketBeat
Canada Pension Plan Investment Board Has $31.58 Million Holdings in Biogen Inc. $BIIB - MarketBeat
BNP Paribas Financial Markets Reduces Position in Biogen Inc. $BIIB - MarketBeat
Trexquant Investment LP Grows Holdings in Biogen Inc. $BIIB - MarketBeat
Multiple Sclerosis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion, Bayer - Barchart.com
Biogen's (BIIB) Hold Rating Reaffirmed at Needham & Company LLC - MarketBeat
Cutter Capital Management LP Makes New $15.53 Million Investment in Biogen Inc. $BIIB - MarketBeat
Why Biogen (BIIB) Is Up 6.4% After At-Home Alzheimer’s Therapy and Dravet Data Updates - Yahoo Finance
Banque Transatlantique SA Makes New $428,000 Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Inc. $BIIB Shares Purchased by AQR Capital Management LLC - MarketBeat
The Manufacturers Life Insurance Company Sells 4,410 Shares of Biogen Inc. $BIIB - MarketBeat
Raymond James Financial Inc. Sells 100,005 Shares of Biogen Inc. $BIIB - MarketBeat
Magnetar Financial LLC Raises Stock Position in Biogen Inc. $BIIB - MarketBeat
Comerica Bank Sells 11,623 Shares of Biogen Inc. $BIIB - MarketBeat
Point72 Europe London LLP Purchases Shares of 82,476 Biogen Inc. $BIIB - MarketBeat
Visual analytics tools that track Biogen Inc. performanceQuarterly Investment Review & Real-Time Buy Zone Alerts - Newser
Is Biogen Inc. stock technically oversoldPortfolio Gains Summary & Daily Stock Trend Watchlist - خودرو بانک
Is Biogen Inc. exposed to political riskPortfolio Update Report & Stock Market Timing Techniques - خودرو بانک
Risk vs reward if holding onto Biogen Inc.Rate Cut & High Win Rate Trade Tips - Newser
Can Biogen Inc. reach all time highs this yearBuy Signal & Free High Return Stock Watch Alerts - خودرو بانک
Signal strength of Biogen Inc. stock in tech scanners2025 Breakouts & Breakdowns & Safe Entry Zone Identification - Newser
Biogen’s IND for BIIB-142 accepted by FDA - BioWorld MedTech
H.C. Wainwright reiterates Buy rating on Biogen stock, citing strong lupus franchise - Investing.com
How institutional ownership impacts Biogen Inc. stock2025 Top Decliners & Technical Buy Zone Confirmations - Newser
B. Metzler seel. Sohn & Co. AG Buys 2,354 Shares of Biogen Inc. $BIIB - MarketBeat
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biogen Inc-Aktie (BIIB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
2.58%
1.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):